(Date:5/20/2008)... cirrhosis, TSP-1 expression has been found to cor...re, TSP-1 expression was higher in rat livers with.... This study, performed by a team led by Dr. Glsm ...be published on April 14, 2008 in the World Journa...) is involved in complex processes including wound...
(Date:5/20/2008)...e/ -- A.S.V., Inc. has been,recognized for its Coh...s a,Minnesota Safety and Health Achievement Recogn...nesota Occupational Safety and Health,Administrati...e managers,and employees work together to develop ...mpliance with all applicable OSHA standards and re...
(Date:5/20/2008)...mmitment to Environmental Health, OAKLAND, Calif....d the,"System for Change" award for environmental ...ronmental Excellence Summit in Pittsburgh., The a...rked to gather,environmental data, set goals, and ...Permanente,s long-standing commitment to protectin...
(Date:5/20/2008)... 90,000 uninsured residents, DETROIT, May 20 /PRN...t,provide low- or no-cost health care to 90,000 un...m Blue Cross Blue Shield of Michigan. The grants,b...4 million since 2005., Supporting free clinics is...de affordable health care and improve access to he...
Breaking Medicine News(10 mins):Health News:A.S.V., Inc. Receives Safety and Health Award 2Health News:A.S.V., Inc. Receives Safety and Health Award 3Health News:Kaiser Permanente Wins National Green Awards 2Health News:Kaiser Permanente Wins National Green Awards 3Health News:Forty-Two Free Clinics Across State Share $1 Million in Grants From Blue Cross Blue Shield of Michigan 2Health News:Forty-Two Free Clinics Across State Share $1 Million in Grants From Blue Cross Blue Shield of Michigan 3Health News:Forty-Two Free Clinics Across State Share $1 Million in Grants From Blue Cross Blue Shield of Michigan 4(Date:5/19/2008)...wswire-FirstCall/ --, - Tasigna(R) (nilotinib) Ef... to Prior Treatment in the Chronic (Early) Phase o...rgeted Nature of Tasigna(R) Tackles the Root Cause...y Profile for Patients(1)(2), - Tasigna Expands C...atment Options for the Majority of Patients With T...
(Date:5/19/2008)...wswire/ -- Helix Health, the first U.S.,stand-alon...e webcast this,Wednesday, May 21, 2008 from 1:00-2...Changing the Management of Breast & Ovarian Cancer...ent.netbriefings.com/event/helixhealth/register.ht...s are diagnosed with cancer.,There is a growing nu...
(Date:5/19/2008)...ire/ -- Ikaria Holdings, Inc., a fully,integrated ...oday that it,has completed dosing of its Phase 1a ...ide) for injection., The study was a Phase 1, ran...center dose escalation study of a single bolus inj...safety, tolerability and pharmacokinetics.,The stu...
(Date:5/18/2008)...duces risk of disease progression by 70%, - RAD001...t after failure, of approved therapies Sutent(R) o... unmet medical need,- Once-daily ...bits mTOR, a protein that controls tumor cell di...tly being studied in multiple types of cancer incl...
Breaking Medicine Technology:Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib) 2Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib) 3Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib) 4Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib) 5Join NPR's David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer 2Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection 2Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection 3RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer 2RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer 3RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer 4RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer 5RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer 6New treatment mechanisms for schizophrenia 1806 1New treatment mechanisms for schizophrenia 1806 2New treatment mechanisms for schizophrenia 1806 3Teens find the benefits of not having sex decline with age 9224 1Teens find the benefits of not having sex decline with age 9224 2Teens find the benefits of not having sex decline with age 9224 3American Association for Cancer Research hosts 2008 annual meeting 9222 1Hays AG Integrates Authentidate 28R 29 Signature Solution for Electronic Invoicing 9220 1Hays AG Integrates Authentidate 28R 29 Signature Solution for Electronic Invoicing 9220 2Hays AG Integrates Authentidate 28R 29 Signature Solution for Electronic Invoicing 9220 3Hays AG Integrates Authentidate 28R 29 Signature Solution for Electronic Invoicing 9220 4...7 /PRNewswire-FirstCall/ --,Nuvelo, Inc. today ann...ism of action and role of NU206 (R-Spondin1) as a ...inal (GI) epithelial cells,will be presented in an...ion for Cancer Research (AACR) Annual Meeting taki...os Angeles, CA, April,14-18, 2007. , , The pres...
... CytImmune, a,clinical stage nanomedicine company ...f multifunctional, tumor-targeted therapies has,be...rd American,Society of Clinical Oncology Annual Me...ssion will take place from 8:00 am to 12,noon on J...l,present the poster abstract entitled "Preliminar...
Other Medicine Technology:Nuvelo Announces Presentation on NU206 at 2007 American Association,for Cancer Research Annual Meeting 2Nuvelo Announces Presentation on NU206 at 2007 American Association,for Cancer Research Annual Meeting 3Nuvelo Announces Presentation on NU206 at 2007 American Association,for Cancer Research Annual Meeting 4CytImmune To Present At ASCO Phase I Clinical Trial of CYT-6091 to,be Presented on June 3, 2007 2Sterile Structural Balloon Trocar (SBT) with Pre-Formed Inelastic Balloon and Foam Collar Anchoring System.
...The Step™ and Mini Step™ device compon... Mini Step™ Single Use System is supplied st... in various configurations and combinations. They ...flation and Access needle and the Step™ radi...
...The Step™ and Mini Step™ device compon... Mini Step™ Single Use System is supplied st... in various configurations and combinations. They ...flation and Access needle and the Step™ radi...
BLUNTPORT Plus Single Use Converterless 5 mm - 12 mm Trocar System for Open Laparoscopy.
Medicine Products: